Perspective Therapeutics Inc
CATX
Get informed when a big investor buys or sells
+ FollowMarket Cap$224.8M
Close$
$0.37
87.6% downside
Current Fair Value
87.6% downsideOvervalued by 87.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $224.80 Million |
|---|---|
| Enterprise Value | $200.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.4 |
| Beta | 1.75 |
| Outstanding Shares | 1,036,040 |
Return
| Return on Equity | -37.36% |
|---|---|
| Return on Assets | -31.60% |
| Return on Invested Capital | -25.01% |
Valuation & Multiples
| P/E Ratio | -0.11 |
|---|---|
| PEG | -0.25 |
| Price to Sales | - |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 385.45 |
| Enterprise Value to EBIT | -2.11 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$157,381
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$90,528
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Perspective Therapeutics Inc
64 employees
CEO: Lori Woods Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.